Retractable Technologies, Inc. — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing was signed March 31, 2015. The company designs, manufactures, and sells safety syringes and related medical devices, principally VanishPoint and PatientSafe products.
Financial performance and position
| Metric | 2014 | 2013 |
|---|---|---|
| Net sales | $34.52 million | $30.79 million |
| Gross profit / margin | $12.02 million / 34.8% | $10.31 million / 33.5% |
| Operating loss | $2.16 million | $5.93 million |
| Net loss | $2.35 million | $6.21 million |
| Loss applicable to common shareholders / diluted loss per share | $3.27 million / $0.12 | $7.13 million / $0.26 |
| Cash flow from operations | $(3.87) million | $2.93 million |
| Cash and cash equivalents at year-end | $22.13 million | $27.63 million |
| Current assets / current liabilities | $34.23 million / $15.10 million | $37.91 million / $16.62 million |
| Total debt, including current maturities | $3.57 million | $3.82 million |
Sales rose 12.1%, with total unit sales up 12.0%. Domestic revenue increased 11.3%; international revenue increased from approximately $5.9 million to $6.9 million. Syringes represented 97.3% of 2014 revenue. Three customers generated 47.9% of sales, compared with 30.2% in 2013.
Gross margin improved as unit costs were slightly lower and volume increased. Operating expenses fell 12.7%, primarily due to lower non-litigation legal costs, compensation, and office expenses. Cost reductions—including a 13.7% workforce reduction—contributed approximately $1.5 million in 2014. Despite improved operating results, operating cash flow was negative, principally reflecting increased receivables, lower current liabilities, and the operating loss.
Year-end cash includes $7.72 million received from BD in 2013 but recorded as a current liability because it remained subject to stipulation. The company reported $600,897 of restricted cash. Working capital was approximately $19.13 million. A $3.57 million bank loan secured by the company’s land and buildings carries a 5.968% interest rate; $2.92 million of its maturities are due in 2019. The filing reports $12.8 million of preferred dividends in arrears. No common dividends have been paid, and none were planned.
Fourth-quarter 2014 sales were $10.72 million, operating income was $751,000, and net income was $702,000; the first two quarters posted operating losses. Fourth-quarter gross margin was 39.8%.
Material changes and management commentary
- 2014 results improved from 2013, when lower domestic pricing and volumes and weaker international sales contributed to an 11.5% decline in total units. 2014’s sales recovery and cost reductions narrowed the annual net loss, but the company remained loss-making.
- Research and development spending declined to $616,784 from $837,073. The FDA issued a notice of substantial equivalence for the EasyPoint retractable needle in June 2014; the filing does not quantify expected commercial contribution.
- The company said it had sufficient cash reserves and intended to fund operations from revenue, reserves, and debt financing when available. It did not intend to raise equity at that time, while noting that additional borrowing was uncertain. Management said further production, workforce, salary, or royalty-payment reductions could be considered if cost measures proved insufficient.
- The 2.3% federal medical-device excise tax cost approximately $856,000 in 2014; the company said it had not passed the tax through to customers.
Litigation, risks, and contingencies
- BD antitrust and false-advertising case: A jury award was trebled, and the District Court entered a January 2015 final judgment of $340.52 million in damages, $11.72 million in attorneys’ fees, and $295,000 in stipulated litigation costs, plus prejudgment and post-judgment interest and injunctive relief. The filing also describes the award broadly as approximately $352 million plus interest. These amounts were not received and were not included in the 2014 financial statements; BD had pending post-judgment proceedings and was expected to appeal. Some end-user notification requirements were stayed pending appeal. The outcome, timing, and collectability remain uncertain.
- Separate patent case: The company received $7.72 million from BD in 2013, but carries it as a current liability pending resolution of the stipulation. BD sought Supreme Court review of a related ruling; the filing says the funds were not yet realizable.
- Competition and market access: The company describes BD as the dominant competitor and says limited hospital access has constrained sales and profitability. Major competitors have greater financial resources, distribution networks, and influence, including long-term contracts.
- Manufacturing and customer concentration: A Chinese manufacturer supplied 73.1% of VanishPoint finished products in 2014. Disruption could require alternative sourcing or a domestic production ramp-up, potentially raising costs. Three customers accounted for 47.9% of revenue.
- Other risks: Some product patents expire in 2015 and 2016; patent litigation is ongoing and unpredictable. Other disclosed risks include supplier availability, product liability and recalls, foreign-market exposure, and the CEO’s voting control. The CEO’s technology license also carries a 5% royalty on gross sales and creates a related-party conflict risk.
Most important facts for investors to verify
- Current status, appellate outcomes, and collectability of the BD judgments, including the distinction between the stated approximately $352 million award and the itemized judgment amounts; confirm whether any proceeds become recognizable or available to the company.
- Cash available for operations after accounting for the $7.72 million litigation liability, restricted cash, continued operating cash burn, and preferred dividend obligations.
- Whether 2014 sales growth and margin improvement continue, and whether the company can gain hospital access while remaining dependent on a concentrated customer base.
- Continuity of Chinese manufacturing and the cost, capacity, and timing of any alternative supply or domestic production plan.
- Patent coverage after the 2015–2016 expirations and commercialization progress for EasyPoint and other products under development.
The independent auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting, with no material weaknesses identified.